Cantargia awards CAN10 manufacturing contract to BioInvent
Sweden-based Cantargia has awarded a contract to BioInvent International for manufacturing CAN10, a monoclonal antibody which is in preclinical development for the treatment of systemic sclerosis and myocarditis. CAN10, which is a fully humanized monoclonal antibody, targets IL1RAP. The monoclonal antibody has been designed to inhibit the signalling of the inflammatory cytokines IL-1, IL-33, and […]